As of November 6, 2026, Relay Therapeutics, Inc. is a publicly traded company (Nasdaq: RLAY); its largest reported holder is Fidelity (FMR), with 10% on Schedule 13G/A of August 7, 2026, then Casdin Capital, LLC (7.5%) (Schedule 13G/A, August 7, 2026).
Is this your company?
About to sign with, pay or invest in Relay Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Relay Therapeutics, Inc. a real, registered company?
- Relay Therapeutics, Inc. files with the SEC under CIK 1812364 (its SEC filings).
- Its shares are listed under the ticker RLAY on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Relay Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Commodore Capital (filed 2026-08-14).
Who are Relay Therapeutics, Inc.'s owners and officers?
Relay Therapeutics, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-01-10)
- : Executive Officer (Form D, 2024-01-10)
- : Executive Officer (Form D, 2024-01-10)
- : Executive Officer (Form D, 2024-01-10)
- : Executive Officer (Form D, 2024-01-10)
- : Director (Form D, 2024-01-10)
- : Director (Form D, 2024-01-10)
- : Director (Form D, 2024-01-10)
- : Director (Form D, 2024-01-10)
- : Director (Form D, 2024-01-10)
- : Director (Form D, 2024-01-10)
- : Director (Form D, 2024-01-10)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Commodore Capital LP | 5.5% |
| Schedule 13G/A, 2026-08-10 | Perceptive Advisors LLC | 6.4% |
| Schedule 13G/A, 2026-08-07 | Fmr LLC | 10% |
| Schedule 13G, 2026-08-06 | Fmr LLC | 9.4% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 0% |
| Schedule 13G, 2026-04-13 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-03-19 | Perceptive Advisors LLC | 5.3% |
| Schedule 13G/A, 2026-02-17 | Casdin Capital, LLC | 7.5% |
| Schedule 13G/A, 2026-02-17 | Casdin Capital, LLC | 7.5% |
| Schedule 13G/A, 2025-11-14 | Commodore Capital LP | 9.9% |
| Schedule 13G/A, 2025-08-14 | Point72 Asset Management, L.P. | 7.8% |
Questions about who owns Relay Therapeutics, Inc.
Who owns Relay Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Relay Therapeutics, Inc.: Fmr LLC (10%, Schedule 13G/A, filed 2026-08-07), Casdin Capital, LLC (7.5%, Schedule 13G/A, filed 2026-02-17), Perceptive Advisors LLC (6.4%, Schedule 13G/A, filed 2026-08-10) and Commodore Capital LP (5.5%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Relay Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Relay Therapeutics, Inc. on this page are Fmr LLC (10%), Casdin Capital, LLC (7.5%) and Perceptive Advisors LLC (6.4%).
When did Fmr LLC buy into Relay Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-08-06, reporting 9.4%; its latest, Schedule 13G/A filed 2026-08-07, reports 10%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Relay Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Relay Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Relay Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Relay Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- SVF Pauling (Cayman) Ltd, a 10% owner: 21,904,963 shares (9.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-28).
- Softbank Vision Fund (AIV M2) L.P., a 10% owner: 21,904,963 shares (9.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-28).
- SB Investment Advisers (UK) Ltd., a 10% owner: 21,904,963 shares (9.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-28).
- , the chief executive and president: 1,358,204 shares (0.61% of shares outstanding), 471,301 held directly and 886,903 indirectly (Form 4, 2026-10-08).
- , the president and r: 396,878 shares (0.18% of shares outstanding) (Form 4, 2026-10-30).
Shares outstanding: 220,959,470 as of 2026-10-30, from the company's latest SEC cover page.
How much has Relay Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-01-10 | $30M | $30M |
Keep reading
More on Relay Therapeutics, Inc. and the records around it.
Relay Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- CASDIN CAPITAL, LLC also filed stake reports on 3 other companies: Standard BioTools Inc. (Jun 2026), BIOLIFE SOLUTIONS INC (Jun 2026), Codexis, Inc. (Nov 2025)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/relay-therapeutics